EGFR and congenital myasthenic syndrome: According to the results of our KEGG pathway analysis, miRNAs enabling a differentiation between CHRNE- and other CMS-patients target (in addition) certain other signalling cascades including HIF1-, Rap1- and ErbB-signalling in addition to neurotrophin signalling.